Royalty Pharma Plc (RPRX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $45.36
• Market Cap: $26.12B
• P/E Ratio: 25.37
• EPS: $1.78
• Dividend Yield: 0.02%
• 52-Week High: $46.14
• 52-Week Low: $28.97

Market Sentiment

Royalty Pharma Plc currently has a Neutral sentiment score of 0.09.

About Royalty Pharma Plc

Royalty Pharma plc, based in New York, is a premier acquirer of biopharmaceutical royalties and a key player in funding innovative therapies within the industry. The company specializes in acquiring royalties from both established and emerging drug portfolios, thereby providing essential capital for ongoing research and development efforts. With its strategic approach to optimizing royalty streams, Royalty Pharma is poised to leverage the expansion of the biopharmaceutical sector, presenting ...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Royalty Pharma Plc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

What is RPRX's current dividend yield?

Royalty Pharma Plc (RPRX) has a current dividend yield of 0.02%.

Does RPRX pay dividends?

Yes, Royalty Pharma Plc pays dividends with a current yield of 0.02%.

What is RPRX's P/E ratio?

Royalty Pharma Plc has a price-to-earnings (P/E) ratio of 25.37.

What is RPRX's market cap?

Royalty Pharma Plc (RPRX) has a market capitalization of $26.12B with a current stock price of $45.36.